# From Cefepime to Colistin: Managing Multidrug-Resistant Pseudomonas aeruginosa in a Ventilator-Dependent Quadriplegic ICU Patient

**Authors:** Esteban Tapias, Marielle Roberts-McDonald, Brian Dunlap, Mikayla Galucia, Muhammad Ali Khalid, Heather L Mateja

PMC · DOI: 10.7759/cureus.86878 · 2025-06-27

## TL;DR

This paper describes the treatment of a ventilator-dependent quadriplegic patient with recurring multidrug-resistant Pseudomonas aeruginosa infections.

## Contribution

The paper presents a clinical case highlighting the challenges of managing multidrug-resistant P. aeruginosa in critically ill patients.

## Key findings

- The patient experienced multiple infections requiring multiple antimicrobial regimen changes due to drug resistance.
- Treatment included cefepime, aminoglycosides, meropenem, aerosolized colistin, and ceftolozane/tazobactam.
- The case underscores the difficulty of treating multidrug-resistant P. aeruginosa in complex ICU patients.

## Abstract

Pseudomonas aeruginosa is a Gram-negative bacterium that is commonly associated with nosocomial infections in hospitals. Due to the increasing prevalence of drug resistance, the clinical management and treatment of P. aeruginosa are becoming a significant challenge. Here, we report the case of a 21-year-old male with a history of traumatic brain injury, quadriplegia, and ventilator dependence who developed recurrent infections caused by P. aeruginosa. Over a span of nine months, the patient was diagnosed with multiple episodes of ventilator-associated pneumonia (VAP) and catheter-associated urinary tract infections (UTIs) requiring intensive care hospitalizations and antimicrobial therapy. Initially, the patient was treated with cefepime and vancomycin; however, due to the rapid rise of multidrug-resistant organisms, the treatment was modified several times with aminoglycosides, meropenem, aerosolized colistin, and ceftolozane/tazobactam. The patient’s case highlights the significant challenge of multidrug-resistant P. aeruginosa and underscores the rapid progression of disease secondary to the complexity of treating infections in critically ill patients.

## Linked entities

- **Chemicals:** cefepime (PubChem CID 5479537), vancomycin (PubChem CID 14969), meropenem (PubChem CID 441130), colistin (PubChem CID 5311054), ceftolozane/tazobactam (PubChem CID 86291594)
- **Species:** Pseudomonas aeruginosa (taxon 287)

## Full-text entities

- **Diseases:** UTIs (MESH:D014552), critically ill (MESH:D016638), nosocomial infections (MESH:D003428), quadriplegia (MESH:D011782), traumatic brain injury (MESH:D000070642), infections (MESH:D007239), VAP (MESH:D053717)
- **Chemicals:** meropenem (MESH:D000077731), Cefepime (MESH:D000077723), vancomycin (MESH:D014640), ceftolozane/tazobactam (MESH:C000594038), aminoglycosides (MESH:D000617)
- **Species:** Homo sapiens (human, species) [taxon 9606], Pseudomonas aeruginosa (species) [taxon 287]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12300544/full.md

---
Source: https://tomesphere.com/paper/PMC12300544